Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 4.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 43,491 shares of the specialty pharmaceutical company’s stock after selling 1,947 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.13% of Collegium Pharmaceutical worth $1,400,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. ProShare Advisors LLC increased its position in Collegium Pharmaceutical by 3.3% in the 1st quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock valued at $343,000 after acquiring an additional 281 shares during the period. Louisiana State Employees Retirement System increased its holdings in shares of Collegium Pharmaceutical by 1.9% in the second quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock valued at $531,000 after purchasing an additional 300 shares during the period. Texas Permanent School Fund Corp raised its stake in shares of Collegium Pharmaceutical by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after purchasing an additional 369 shares during the last quarter. SummerHaven Investment Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 1.3% during the second quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock worth $1,120,000 after purchasing an additional 452 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Collegium Pharmaceutical by 1.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock worth $1,137,000 after purchasing an additional 535 shares during the period.

Collegium Pharmaceutical Stock Down 2.7 %

Shares of NASDAQ COLL opened at $37.42 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The firm has a 50-day moving average price of $34.67 and a 200 day moving average price of $35.26. Collegium Pharmaceutical, Inc. has a 52 week low of $20.95 and a 52 week high of $40.95. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of 15.59 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. The company had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm earned $1.13 EPS. Equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and increased their price target for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Piper Sandler restated a “neutral” rating and issued a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Truist Financial boosted their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright raised Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price target for the company in a report on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.